SUMMARY -Epilepsy is the most common neurological complication in pregnancy. Women with epilepsy have a higher risk of complications in pregnancy. In Croatia, women with epilepsy are treated by neurologists at tertiary centers according to the place of residence. We prospectively followed-up pregnancies in women with epilepsy and healthy controls, and analyzed the factors responsible for their delivery outcomes and development of their babies. Healthy pregnant women had a higher level of education and economic status, but pregnant women with epilepsy took folic acid in a higher proportion than controls, possibly due to timely preconception counseling. Complications during pregnancy depended on the number of antiepileptic drugs and epilepsy control. We noticed some behavioral and cognitive aspects in children exposed in utero to valproic acid, which required follow up. Th e rate of congenital malformations was not increased. In conclusion, women with epilepsy should receive preconception counseling about the risk for pregnancy, but also about the possibilities to minimize that risk. We have introduced a model of integrative management of pregnancy and epilepsy based on close collaboration among diff erent clinical experts in Croatia, in order to provide prompt counseling and timely intervention.
Introduction
About 50 million people worldwide suff er from epilepsy, including women of fertile age. Epilepsy is the most common neurological complication in pregnancy. Women with epilepsy have a higher risk of complications in pregnancy as compared with healthy ones, e.g., the risk of hyperemesis gravidarum is almost twofold, preterm pregnancy threefold, hypertension in pregnancy-preeclampsia almost twofold, cesarean section and placental rupture twofold to threefold, and perinatal mortality up to eight times greater 1 . Considering that 0.3%-0.6% of all pregnant women have epilepsy and therefore 1 of 250 embryos/fetuses is exposed to antiepileptic drugs (AEDs), it is worth eff orts of health professionals to try to improve the quality of management in such pregnancies 2 . In general population, there is a 3%-4% risk of having a child with major congenital anomaly. About 10% of these anomalies can be attributed to maternal drug intake, exposure to chemical substances, infections, or familial disease. Pregnant women with epilepsy are at a higher risk of unfavorable outcome of pregnancy because of taking diff erent types of AEDs as potential teratogens, the possibility of epileptic seizure impairment, genetic factors, and comorbidities [2] [3] [4] . Adverse AED eff ects on the embryo or fetus can present as fetal loss, intrauterine growth retardation (IUGR), congenital malformations, impaired postnatal development, and behavior problems.
Despite eff orts invested so far, some risk factors for unfavorable obstetric outcomes in women with epilepsy remain inadequately understood. Complex metabolic and excretion interactions between the mother and the fetus in case of epilepsy are misbalanced due to the impact of AED on sex steroid levels and possible other disturbances of maternal homeostasis. Th ere are no suffi cient studies of the impact of AED on the level of steroid hormones and non-steroids during pregnancy, delivery and puerperal period. Bag et al. compared the sex steroid hormone levels during pregnancy between the groups with increased and not increased seizure frequency. Th e increased seizure group had signifi cantly higher estrogen levels, lower levels of progesterone, and lower levels of AEDs. In addition, the authors noted that patients having had abortions and those having developed epileptic status had high serum estrogen levels 5 . Falling serum levels of progesterone may be associated with increased seizure frequency, and may be most prevalent around parturition 6 . Th ere is a higher risk of adverse eff ects in such pregnancies regardless of AED therapy, but it is mostly connected with AED intake. Th e risk is higher in longer duration and treatment of epilepsy. In pregnant women on monotherapy, the risk is 2.9% for lamotrigine (LTG), carbamazepine (CBZ) and oxcarbazepine (OXC) to 7.2% for valproic acid (VPA) 2, 7, 8 . Th e risk is twice higher with the intake of 2 or more AEDs or with high AED concentration in plasma. Th e incidence of malformations in children is highest (12.7%) in women taking more AEDs and having seizures during pregnancy 2, 7, 8 . Preconception counseling is the process of planning and preparing for pregnancy and gaining optimal balance of physical, emotional and mental health before conception. In women with epilepsy, preparing for pregnancy includes analysis of previous antiepileptic treatment in order to minimize the risk factors for both the fetus and the mother.
Patients with epilepsy in Croatia are usually treated in tertiary level centers by subspecialists (neurologists and pediatric neurologists) and women with epilepsy are referred by their primary care physicians to hospital according to the place of residence. Primary care practitioners follow the instructions from tertiary level specialists without active involvement in therapy switch. According to this issue, the greatest responsibility is on the neurologist, who must be timely informed about the possible pregnancy in order to adjust patient therapy.
Material and Methods
Th is article describes prospective surveillance of pregnant women with epilepsy from May 2003 till May 2013 at the Sestre milosrdnice University Hospital Center in Zagreb, Croatia. All data were obtained from women with epilepsy and their documentation during outpatient visits to the neurologist, gynecologist and pediatrician neurologist. Data collected on pregnant women included age, socio-demographic data (marital status, income and education), smoking habit, previous loss of pregnancy or children, parity, actual pregnancy planning, type of epilepsy, electroencephalography (EEG) fi ndings, AED dosage before and during pregnancy, actual pregnancy data (folic acid intake, vitamin K, seizures during pregnancy, ultrasound (US) fi ndings and complications). Prenatal US and other relevant prenatal testing was performed as requested by the gynecologist or pediatrician/geneticist (triple test, amniocentesis, etc.). Newborns were examined by pediatrician neurologist/geneticist at Clinical Department of Pediatrics and followed up yearly till school age. Data on newborns/children included term/mode of delivery, Apgar score, body weight, body height, and early psychomotor development. Results were compared with those in healthy control subjects. Detailed examination of the newborn included anthropometric measurements, clinical features, if relevant, photos of dysmorphic features, search for minor and major anomalies, and yearly evaluation of neurological development. When needed, psychological testing was performed including evaluation of intellectual capacities in older children (Kohs, numeric factor, social functioning, dictionary, perceptive motor skills, motor velocity as measure of concentration, attention span, Bender gestalt, etc.). All newborns underwent screening for hearing. Other fi ndings were also included if needed (brain US, ECHO, abdominal US, karyotyping, brain computed tomography (CT) or magnetic resonance imaging (MRI), vision, etc.).
Data on the control group were obtained from Clinical Department of Gynecology and Obstetrics and included age, socio-demographic data (marital status, income and education), pregnancy planning, smoking habit, previous loss of pregnancy or children, parity, actual pregnancy planning, actual pregnancy data (folic acid intake, vitamin K, US fi ndings, complications and pregnancy outcome). Mothers with chronic diseases and smokers were excluded from the study. Data on newborns from the control group were collected prospectively from Clinical Department of Gynecology and Obstetrics and Clinical Department of Pediatrics and included delivery term and mode, Apgar score, body weight and body height. Examination of the newborns included anthropometric measurements, clinical features, search for minor and major anomalies, and neurological evaluation. 
Statistics

Standard protocol approvals, registrations and patient consents
Th e researchers contacted all women included and obtained their written consent prior to inclusion in the study. Th e study was approved by the Ethics Board of the Sestre milosrdnice University Hospital Center in Zagreb, and was performed in accordance with ethical standards laid down in the 1964 Declaration of Helsinki.
Results
During the period from May 2003 till May 2013, we prospectively followed-up 74 pregnancies in women with epilepsy (group 1) and 147 healthy controls (group 2). Th e average age was 34 (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) 
Socio-demographic status
Socio-demographic status of the two groups of pregnant women is shown in Table 1 . Healthy pregnant women had a signifi cantly higher level of education and economic status, whereas there was no between-group diff erence according to marital status ( Table 1) .
Smoking
Th e association of smoking and delivery outcome (premature delivery and spontaneous abortion) was evident in the group of women with epilepsy. Th ere were six smokers, of which three had early spontaneous abortions and one had premature delivery at 36 weeks + 5 days. Control group of healthy women were non-smokers during pregnancy and there was no case of spontaneous abortion in this group.
Folic acid intake and preconception counseling of epileptic women
Healthy controls planned their pregnancy in a signifi cantly higher number of pregnancies (114/128 or 89.06%) as compared to 35% (26/74) of women with epilepsy (Table 1) . About 60% of pregnant women with epilepsy had received preconception counseling as compared to none in the control group and about 20% of women with epilepsy took folic acid (FA) properly, as compared to only 2.7% in the control group (Table 1) . Even more, pregnant women with epilepsy having attended preconception counseling had signifi cantly less spontaneous abortions and stillbirths as compared to those not having received preconception counseling (Fig. 1) .
Antiepileptic therapy
Monitored women with epilepsy during pregnancy were prescribed diff erent types of AED: LTG, VPA, phenytoin (PHT), phenobarbitone (PB), gabapentin (GBP), topiramate (TPM), CBZ, clonazepam (CZP), and OXC. In 62 of 70 (88.6%) monitored pregnancies, women were on monotherapy: mostly (37/62) on LTG, 13/62 on CBZ, 6 on VPA, 3 on PB, 1 on OXC, 2 on GBP, and 1 on PHT. Eight pregnancies (8/70 or 11.4%) were on polytherapy with the following combinations: TPM/VP, LTG/CBZ, CBZ/PB, TPM/ CBZ/PHT and VP/CZP. Four pregnant women were without AEDs.
Seizures
About 40% of women with epilepsy in our study had seizures during pregnancy. A higher proportion of women on polytherapy (63%) had seizures during pregnancy as compared to those on monotherapy (37%) ( Table 2 ). None had status epilepticus during pregnancy. Th ere was no diff erence in the mode of delivery (vaginal or cesarean section) between the groups with epilepsy and healthy controls, but women with seizures during pregnancy delivered with cesarean section more frequently than those without seizures. Th e AED dosage had to be increased in 53% of pregnancies (50% on monotherapy and 75% on polytherapy) and to switch AED in 26% of pregnancies (23% on monotherapy and 50% on polytherapy) ( Table 2) . 
Mode of delivery and anthropometric measurements of neonates
When we cut out women with early spontaneous abortions in the epileptic group, there was no statistical diff erence in the mode of delivery between the control and epileptic women. In each group, 25% of women had cesarean section performed (25% or 36/147 vs. 25% or 16/64). Th ere were no statistical diff erences in neonatal birth length or birth weight between the women with epilepsy and healthy controls, except for the group under 500 g, due to stillbirths/spontaneous abortions in mothers with epilepsy. Th e neonates of healthy controls had a signifi cantly better Apgar score (p=0.004; D=0.205) ( Table 3) .
Adverse eff ects on embryo or fetus
Healthy controls had a signifi cantly lower number of complications in pregnancy (p<0.0001; D=0.246). Furthermore, when we compared women with epilepsy according to the number of AEDs, about 40% of pregnancies on AED polytherapy resulted in various complications as compared to 20% of pregnancies on AED monotherapy (Table 4) . Moreover, monitoring of pregnancies on monotherapy with VPA and CBZ revealed that AED polytherapy involving VPA and CBZ with diff erent AEDs resulted in a larger proportion of complications and adverse outcomes as compared to monotherapy with those AEDs (Table 4) .
Fetal loss
Fetal loss occurred in 9/74 followed-up pregnancies in women with epilepsy. It was due to intrauterine death, spontaneous abortion, or stillbirth. In comparison to the control group, there was a signifi cantly higher number of spontaneous abortions in women with epilepsy (p=0.001; D=0.081). Artifi cial abortion is legal in Croatia until 10 th week of gestation and one woman with epilepsy on LTG therapy decided to terminate pregnancy before 10 weeks of gestation for fear from adverse eff ects in pregnancy.
Intrauterine growth retardation (IUGR)
In our study, 2 live births were surveyed prenatally because of IUGR. Th e fi rst one was exposed to CBZ/ Fig. 1 TPM/PHT and during follow up remained with short stature and facial features indicative of the possible fetal anticonvulsant eff ect ( Fig. 2A and B ), but had normal psychomotor development. Th e other one was exposed prenatally to GBP. He had atrial septal defect discovered after birth and delayed psychomotor development. He suff ers from intractable myoclonic epilepsy since infancy. Th e extensive work-up excluded chromosomal aberration and inherited metabolic disorder, and no specifi c syndrome was revealed by the geneticist.
Major congenital malformations, pervasive and behavioral aspects, and cognitive abilities
Out of 74 prospectively followed-up pregnancies with epilepsy, one child (1/74 or 1.4%) prenatally exposed to GBP had congenital heart defect (atrial septal defect), while no congenital anomalies at birth were . Th e above mentioned child exposed to polytherapy with CBZ/TPM/PHT, with IUGR, born on term from the fourth pregnancy, had dysmorphic facial features in accordance with fetal anticonvulsant eff ect (Fig. 2) . He was prospectively followed-up till school age, his psychomotor development is normal and he has no congenital malformations. Two boys, one exposed to LTG and other one to VPA, had the spectrum of attention defi cit hyperactivity disorder. Th e boy exposed to LTG had behavioral disturbances accompanied with aggression, stubbornness and learning diffi culties. One girl, exposed in utero to VPA had attention defi cit hyperactivity disorder, and slight psychomotor and speech developmental delay. Her mother had one spontaneous abortion from pregnancy on VPA and TPM. All three children were prospectively followed-up, and they all had one-year delay in starting school due to diffi culties in fi ne motor skills, expressive language skills and attention defi cit, and hyperactivity. We had no children with clear evidence for autistic spectrum disorder, especially regarding the group of children prenatally exposed to VPA.
Discussion
Socioeconomic status of epileptic pregnant women
In the current study, healthy pregnant women had signifi cantly better levels of education and economic status. According to previous reports, fi nancial issue is a major problem for patients with epilepsy 9 . Th e longer the duration of epilepsy, the worse the psychological issues are 10, 11 . Epileptic patients have poor education and achievement later in life 10 . Patients who have epilepsy at school age have worse learning achievement 10 . Campbell et al. observed no diff erence in the rate of major congenital anomalies between the groups of women with low income and education and those with higher income and education 12 . Less deprived women were more likely to take preconception FA and less likely to have generalized tonic-clonic seizures in pregnancy than socially deprived ones. Th ey also were more likely to be on monotherapy, less likely to be on VPA, and more likely to be on lower doses of the drug compared to socially deprived ones 12 . As diff erences in treatment between socioeconomic groups do exist, particularly in preconception FA consumption, AED choice and seizure frequency, there should be benefi t from preconception counseling for women with low socioeconomic status, to discuss AED choice and FA intake and to improve chances for normal pregnancy and delivery.
Smoking
Lower birth weight of newborns of all gestational ages was observed in teenage and adult mothers with epilepsy who smoked 13 , as well as negative eff ect of maternal smoking on fetal growth 14 . Our data on 24% of pregnant women smoking during pregnancy in Croatia are more or less consistent with the recently published data on 50% of Croatian pregnant women having smoked before pregnancy and 19% continuing smoking during pregnancy 15 . It has already been proposed that women with epilepsy who smoke be warned that they possibly are at a substantially higher risk of premature contractions and premature labor and delivery 16 , and we promote this attitude during counseling of women with epilepsy in Croatia. In the group of women with epilepsy, there was strong association of smoking and early spontaneous abortions; these women did not take FA during pregnancy, one-third of them had seizures during pregnancy, and it was difficult to observe only smoking as a variable because of the small number of women. Th e lower proportion of smokers in the group of women with epilepsy despite lower socioeconomic status as compared to healthy women could also be the result of our continuous counseling about epilepsy and pregnancy.
Folic acid intake and counseling of epileptic pregnant women
As the majority of AEDs antagonize folate action, children born to women taking antiepileptic therapy are at an increased risk of birth defects. Th us, it is suggested that women with epilepsy take FA supplementation, especially in case of VPA therapy 17 . Pittschieler et al. analyzed 388 pregnancies in 244 patients and pregnancies with FA supplementation showed significant reduction of spontaneous abortion. In the group of women taking VPA as monotherapy, supplementation of FA had signifi cant benefi t. Other examined monotherapies (CBZ, PHE, and PB) known to interfere with FA showed no signifi cant results. Th is study confi rmed the prophylactic eff ect of FA supplementation on spontaneous abortion and the fact that FA supplementation should be included in therapy of every pregnant epileptic woman, especially those treated with VPA 18 . In the NEAD study of children exposed in utero to AED, maternal periconceptional folate intake was associated with higher IQ of their children at the age of six, but the authors concluded that this fi nding should be interpreted with caution because periconceptional folate was one of several confounding variables, and was established by retrospective maternal interview in the study of neurodevelopmental effects of AEDs 19 . In our study, the women with epilepsy having received prenatal counseling planned their pregnancies in a higher proportion as compared to the women with epilepsy without prenatal counseling. Sample size in our study was too small to determine whether FA protects against birth defects, but our surveillance showed that the prenatally counseled women with epilepsy took FA in a higher proportion and had signifi cantly less fetal losses and stillbirths. Due to the fact that our surveillance was prospective, we can argue that preconception counseling in women with epilepsy could have resulted in a higher proportion of proper FA intake in women with epilepsy, despite the higher proportion of planned pregnancies in control subjects.
Seizures
Among pregnant women with epilepsy, the severity of the seizure disorder is in concordance with the increased risk of adverse fetal outcomes 20 as a consequence using higher AED doses and polytherapy. It has been reported that >5 convulsions during preg-nancy reduced cognitive levels in newborns 21 . Th e effects of AEDs on the child's cognitive outcome cannot be explained only by the severity of the maternal seizure disorder, as assessed in the analysis for the NEAD study and additional research is suggested. Th e increased volume of distribution and the hepatic metabolism of AEDs, along with decreased compliance during pregnancy and self-initiative interruption of AED intake because of concerns about their eff ects on the fetus, lead to an increase in seizure frequency during pregnancy in women with epilepsy. Seizures in women with epilepsy are observed in as many as 17%-40% of pregnancies 22, 23 . In our study, 40% of women with epilepsy had seizures during pregnancy, but owing to close drug monitoring, AED increase (especially LTG) or therapy switch we had no epileptic status and no signifi cantly increased percentage of complications in women with seizures during pregnancy, except for the higher number of cesarean sections.
Mode of delivery and anthropometric measurements
About 5% to 25% of deliveries in Croatia end up with cesarean section, depending on the hospital level and pathology of the population served. Th e most frequent specifi c indications for cesarean section in Croatia are cesarean section in previous pregnancy, prolonged delivery, fetal dystocia, and cardiotocography fi ndings that require emergency delivery. Since both of our groups included women followed-up at a tertiary center where there is usually a higher percentage of cesarean sections, the higher percentage recorded in our study is not surprising. Although we had no data on the specifi c reasons of cesarean section in every woman, the fact is also that cesarean section performed upon patient request has been increasing in Croatia and in nearby countries 24 . Th e higher risk of Apgar score <7 in deliveries of women with epilepsy was also noticed by some authors 25 . It was not possible to identify specifi c factors for lower Apgar score in this study, except for preterm deliveries also resulting in lower birth weight.
Fetal loss
Since pregnancy loss can occur very early in pregnancy, it is hard to estimate the true fetal loss in pregnant women. Nine fetal losses (9/74 or 11.4%) in the epileptic group in the current study (7 spontaneous abortions and 2 stillbirths) were higher than some previously published data 18, 25 . Th omas et al. showed a higher rate among women with epilepsy (4%) than in controls (2%). Th e risk was higher in women on valproate (8%) than in those on other AEDs (1%-6%) 25 . Pittschieler et al. report results of a non-randomized, partly retrospective study with 10% of spontaneous abortions in women with epilepsy and a lower range of spontaneous abortion among those using FA supplementation 18 . Our results also suggested a signifi cantly higher risk of spontaneous abortion in epileptic pregnancies as compared to controls. One important result was a signifi cantly lower risk of spontaneous abortion in women with epilepsy having received preconception counseling. Women in this group also took FA in a higher percentage than non-counseled ones. Th e group of women with epilepsy had a signifi cantly higher FA supplementation as compared to controls, despite the higher proportion of planned pregnancies in controls. We can only suppose that preconception counseling enabled higher FA intake in women with epilepsy and possibly infl uenced the reduced risk of fetal loss in their pregnancies. Th e fact that a large proportion of fetal loss in general population is associated with chromosomal abnormalities and many occur too early to be recognized makes it diffi cult to estimate the true incidence of fetal loss due to epilepsy/AED. Furthermore, there are no larger studies with consistent data on chromosomal aberrations in pregnancies of women with epilepsy 26, 27 . We can assume that the signifi cant diff erence in fetal loss between these two prospectively followed-up groups was in connection with epilepsy and its potential to cause complications during pregnancy.
Intrauterine growth retardation
Th ere are some data that AEDs can infl uence fetal growth suggesting an increasing risk of small for gestational age newborns exposed to AED in utero 28 . Some studies have shown that CBZ and VPA as monotherapy during pregnancy reduce the mean body weight-adjusted head circumference and that AED polytherapy increases the rate of microcephaly. According to these studies, the possible signifi cance for further development of the child is uncertain and should be explored 29, 30 . In our study, two live births were surveyed prenatally because of IUGR. Th e fi rst one was exposed to CBZ/TPM/PHT and remained with short stature during follow up, but also with facial dysmorphism due to the fetal anticonvulsant eff ect ( Fig. 2A and B) . Th e second case of IUGR was exposed to GBP, with cardiac anomaly (atrial septal defect) discovered after birth, had delayed psychomotor development during follow up, and started to suff er from intractable myoclonic epilepsy in infancy. Karyotype was normal in both cases.
Congenital malformations, pervasive and behavioral aspects, and cognitive abilities
Th e extensive metabolic and genetic work-up found no specifi c syndrome in the boy prenatally exposed to GBP with psychomotor and somatic delay, generalized epilepsy and congenital heart anomaly. GBP has no specifi c pattern of congenital anomalies and data support the safety of GBP use in pregnancy; however, the number of exposures to date is still small 31 . Th e rate of 2.7% of major congenital anomalies in our group of women with epilepsy was in accordance with the rate of major congenital malformations in general population, but it was still higher in the group of women with epilepsy as compared to healthy controls with no congenital malformations found at birth (c 2 -test=9.514; DF=2; signifi cance level p=0.0086; contingency coeffi cient 0.201).
Th e boy exposed prenatally to CBZ/TPM/PHT ( Fig. 2A and B) was born from irregularly controlled pregnancy at another institution. Th e mother came to our institution in 16 th week of pregnancy, when we excluded CBZ from therapy and she remained on TPM and PHT, seizure free during pregnancy. Characteristic dysmorphic features have been described so far with fetal exposure to phenytoin, valproate, and CBZ. Fetal phenytoin is said to be associated with hypertelorism, broad nasal bridge, short nose, and facial hirsutism, while fetal CBZ face includes epicanthic folds, short nose, long philtrum, and upward slanting palpebral fi ssures, as in our patient mentioned above [32] [33] [34] . Although distinctive phenotypes have been described for diff erent anticonvulsants, there is an overlap in both facial dysmorphic features and malformations.
Fetal anticonvulsant syndromes also consist of behavioral phenotype 34 . Of the three children with attention defi cit/hyperactivity disorder (ADHD) in our study, the boy exposed prenatally to LTG improved his social skills with time and he attends regular school, but the other two children prenatally exposed to VPA are still under surveillance, psychotherapy and rehabilitation. Th e recently published data implicate that prenatal exposure to valproate can be associated with autistic spectrum disorder in the off spring, even after adjusting for maternal epilepsy 35 . It is recommended that this important information be shared with women of childbearing potential within the counseling when discussing treatment options that include valproate 36, 37 . Taking this into account, in our group of women on VPA treatment we also balanced against the treatment benefi ts for women requiring valproate for epilepsy control and made therapy switch where possible (Table 4) .
According to the NEAD study, fetal VPA exposure has dose-dependent associations with reduced cognitive abilities across a range of domains at 6 years of age and the positive association of periconceptional folate with IQ was consistent with other recent studies 19 . In this study, the mother of the child with mental delay and mothers of children with ADHD did not take FA periconceptionally, nor did the mother of the boy with fetal anticonvulsant syndrome. Bromley et al. compared the prevalence of neurodevelopmental disorders diagnosed in 415 children exposed in utero to diff erent AEDs, and autistic spectrum disorder was the most frequent diagnosis. No signifi cant increase was found among children exposed to CBZ or LTG 38 . An accumulation of evidence so far demonstrates that the risks associated with prenatal sodium VPA exposure include an increased prevalence of neurodevelopmental disorders 39, 40 . Th e European Medicines Agency (EMA) has strengthened warnings on the use of VPA in women and girls (EMA November 21, 2014). As these restrictions have been incorporated in the amended Summary of Product Characteristics (SmPC) and package leafl ets in all EU member states, the Commission of European Aff airs of the International League Against Epilepsy (CEA-ILAE) and the European Academy of Neurology (EAN) have appointed the Task Force and published recommendations for clinical use of VPA in the treatment of girls and women with epilepsy in the context of these new restrictions 41 . Th ese Task Force's recommendations include the following: 1) where possible, valproate should be avoided in women of childbearing potential; 2) the choice of treatment for girls and women of childbearing poten-tial should be based on a shared decision between clinician and patient, and where appropriate, the patient's representatives. Discussions should include careful risk-benefi t assessment of reasonable treatment options for the patient's seizure or epilepsy type; 3) for seizure (or epilepsy) types where valproate is the most eff ective treatment, the risks and benefi ts of valproate and other treatment alternatives should be discussed; 4) valproate should not be prescribed as a fi rst-line treatment for focal epilepsy; 5) valproate may be offered as a fi rst-line treatment for epilepsy syndromes where it is the most eff ective treatment, including idiopathic (genetic) generalized syndromes associated with tonic-clonic seizures; 6) valproate may be off ered as a fi rst-line treatment in situations where pregnancy is highly unlikely (e.g., signifi cant intellectual or physical disability); and 7) women and girls taking valproate require regular follow-up for ongoing consideration of the most appropriate treatment regimen 41 . For newer AEDs, one multicenter, observational prospective cohort study conducted by our ENTIS colleagues in 2016 demonstrated a signal for an increased risk of major birth defects after fi rst trimester exposure to pregabalin, but these results need confi rmation through independent studies 42 . Newer data also suggest that lamotrigine and levetiracetam are associated with a relatively low risk for both anatomic and developmental adverse eff ects, although further studies are needed for these and other AEDs 43 .
Th e model of management of epilepsy in pregnancy in Croatia
Croatia is a south-eastern European country, with about 4,500,000 inhabitants. Th e incidence, prevalence and mortality of epilepsy vary across countries with diff erent economies 44 , and according to Bielen et al. , it is likely that the prevalence of active epilepsy in Croatia is between 4.8 and 5.5/1000 45 . In Croatia, neurologists and pediatric neurologists are usually taking care of the people with epilepsy and general practitioners follow their advice and proceed with drug prescriptions. Th e usual frequency of outpatient visits to tertiary centers is every 3-6 months, depending on the severity of epilepsy. Our clinical hospital center has the 3 rd largest maternity hospital in the country, with 3200 deliveries per year. If we consider the previous fact that 1 of 250 embryos/fetuses are exposed to AED 1 , we can expect about 13 newborns exposed in utero to AEDs in our maternity hospital each year. Our health professionals working in the maternity hospital frequently have some issues with pregnant women with epilepsy. In order to improve the quality of management in such pregnancies, we have developed close collaboration among diff erent specialists (gynecologists, neurologists, neonatologists and pediatric neurologists/geneticists). Th is collaboration has resulted in a prospective registry of pregnant women with epilepsy dating from 2003, and in scientifi c collaboration with institutions such as the Institute for Medical Research and Occupational Health in Croatia. After formation of the Teratology Information Service at the Department of Pediatrics in 2004 (TIS Zagreb, since 2010 at Srebrnjak Children's Hospital) and the Center for Counseling for Epilepsy and Pregnancy at the Clinical Department of Neurology, Sestre milosrdnice University Hospital Center, Sestre milosrdnice, women with epilepsy can be prospectively followed-up, off ered prepregnancy counseling at the proper time, prospectively follow-up their pregnancy and children, from the neonatal period till school age or after it if needed.
Conclusion
Our model of the integrative management of pregnancy and epilepsy includes close collaboration among clinical experts in neurology, gynecology, pediatrics and primary health care professionals (Fig. 3) . Every woman with epilepsy in generative age should receive preconception counseling. Women with epilepsy should be encouraged to attend pre-pregnancy counseling during their ordinary follow up visits, using tickets from their primary health professionals, or as an emergency expertise if needed. Pregnant woman with epilepsy has to be counseled about the risk that her disease can bring, but also about the possibilities to minimize the risk by appropriate treatment, good control of epilepsy, quality of nutrition, vitamin intake, screening for congenital anomalies, and careful surveillance of pregnancy and delivery. Women with epilepsy that smoke should be counseled that they possibly have a substantially increased risk of premature contractions and premature labor and delivery.
Planned pregnancy with periconceptional FA intake increases the possibility of favorable outcome of pregnancy in women with epilepsy. Monotherapy and the lowest possible dose of AED in pregnant women with epilepsy can lower the risk of congenital anomalies. Of newer AEDs, lamotrigine has the best documented data on the use in pregnancy. After being exposed to AED, no termination of pregnancy is indicated, but prenatal surveillance is needed as in other AED exposures, including alpha-fetoprotein screening and US examinations (anomaly scan). Frequent monitoring of LTG (and OXC) concentrations (at least monthly) is very helpful, with dose adjustment before, during and after pregnancy. Individual approach to every pregnant woman is advised because of inter-individual variations in pharmacokinetics.
Our study was limited by the small number of pregnancies on the same AED, but the intention of this study was not to analyze the eff ect of each AED on the fetus, but the benefi ts of the integrative model of pregnancy follow up in epilepsy.
